Ivosidenib (Tibsovo): AML & Bile Duct Cancer Treatment
Ivosidenib works differently from traditional chemotherapy. Instead of just killing cells, it acts as a "re-educator." It targets a specific mutation in the IDH1 gene that prevents blood cells from maturing, causing them to multiply as cancerous blasts.
Ivosidenib (Tibsovo) blocks this mutant enzyme, allowing these immature cancer cells to grow up and differentiate into normal, functioning blood cells. This unique mechanism offers hope for patients with Acute Myeloid Leukemia (AML) and Bile Duct Cancer.
It is an oral targeted therapy designed for patients whose cancer carries the specific IDH1 mutation.
Indications
- Acute Myeloid Leukemia (AML):
- Newly diagnosed adults who are not candidates for intensive chemotherapy (due to age or comorbidities).
- Adults with relapsed or refractory AML.
- Cholangiocarcinoma: Previously treated, locally advanced or metastatic bile duct cancer.
- Requirement: Effective only in patients with a susceptible IDH1 mutation confirmed by an FDA-approved test.
Dosage and administration
The dosing schedule is simple but strict regarding food.
- Standard Dose: 500 mg (two 250 mg tablets) taken orally once daily.
- Instructions: Swallow whole with water at the same time each day. Do not split, crush, or chew. Can be taken with or without food, but avoid high-fat meals near dosing time, as fat can dangerously increase drug absorption.
- QTc Prolongation: Patients with existing heart rhythm issues.
- Concomitant use of strong CYP3A4 inhibitors.
- Pregnancy and breastfeeding.
The most critical risk comes from the drug's mechanism of action: Differentiation Syndrome.
- Differentiation Syndrome (Emergency): As cancer cells mature rapidly, they can release cytokines causing fever, shortness of breath, and rapid weight gain/swelling. Seek medical help immediately if these occur.
- Heart: QTc prolongation (ECG monitoring is required).
- General: Fatigue, diarrhea, nausea, joint pain, and leukocytosis (high white blood cell count).
